The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway

Pharmacology and Therapeutics

Volumn 93, Issue 2-3, 2002, Pages 225-232

  Sasaki, Yasuharu ^a   Suzuki, Masaaki ^b   Hidaka, Hiroyoshi ^c  

^a KITASATO UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c D Western Therapeutics Institute   (Japan)

Author keywords

H 1152; LPA; MARCKS; Rho kinase; Synthetic inhibitor

Indexed keywords

2 METHYL 1 [(4 METHYL 5 ISOQUINOLINE)SULFONYL]HOMOPIPERAZINE; ANTIBODY; CYCLIC AMP DEPENDENT PROTEIN KINASE; FASUDIL; H 1152P; LYSOPHOSPHATIDIC ACID; MARCKS PROTEIN; MYOSIN LIGHT CHAIN; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOTRANSFERASE INHIBITOR; RHO KINASE; SERINE; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 METHYL 1 ((4 METHYL 5 ISOQUINOLINYL)SULFONYL)HOMOPIPERAZINE; 2-METHYL-1-((4-METHYL-5-ISOQUINOLINYL)SULFONYL)HOMOPIPERAZINE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSIDASE; MEMBRANE PROTEIN; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; PHOSPHOPROTEIN; PRKCSH PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE;

ANTIBODY SPECIFICITY; ARTERY SPASM; ARTICLE; BIOCHEMISTRY; BRAIN ARTERY; BRAIN VASOSPASM; CELL FUNCTION; CELL STIMULATION; CELL STRAIN; CLINICAL TRIAL; CORONARY ARTERY SPASM; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HYPERPLASIA; MOLECULAR WEIGHT; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SMOOTH MUSCLE CONTRACTION; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; ANIMAL; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; RABBIT; REVIEW; VASCULAR SMOOTH MUSCLE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CLINICAL TRIALS; CORONARY DISEASE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; GLUCOSIDASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RABBITS; VASOSPASM, INTRACRANIAL;

EID: 0035990918     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00191-2     Document Type: Review

References (40)

1. A role for MARCKS, the alpha isozyme of protein kinase C and myosin I in zymosan phagocytosis by macrophages
2. Mechanism of action of a novel antivasospasm drug, HA1077
3. A critical role for a Rho-associated kinase, pl60ROCK, in determining axon outgrowth in mammalian CNS neurons
4. Is pharmacological neuroprotection dependent on reduced glutamate release?
5. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis
6. 2+ channel which is coupled glutamate exocytosis
7. Transmitter release: Target of regulation by protein kinase C?
8. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: Its specific localization in smooth muscle
9. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells
10. Activation of protein kinase C-alpha and translocation of the myristoylated alanine-rich C-kinase substrate correlate with phorbol ester-enhanced noradrenaline release from SH-SY5Y human neuroblastoma cells
11. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin
12. Pharmacology of protein kinase inhibitors
13. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C
14. Inhibition of Rho-kinase-induced MARCKS phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor
15. Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors
16. Enhanced myosin light chain phosphorylation as a central mechanism for coronary artery spasm in a swine model with interleukin-1β
17. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility
18. Rho family GTPases and neuronal growth cone remodelling: Relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid
19. Nitric oxide: A downstream mediator of calcium toxicity in the ischemic cascade
20. Contractile and relaxant effects of phorbol ester in the intestinal smooth muscle of guinea-pig taenia caeci
21. Lysophosphatidic acid: G-protein signalling and cellular responses
22. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells
23. Rho-associated kinase phosphorylates MARCKS in human neuronal cells
24. Rho effectors and reorganization of actin cytoskeleton
25. Direct evidence for a key role of protein kinase C in development of vasospasm after subarachnoid hemorrhage
26. H-series protein kinase inhibitors and potential clinical applications
27. The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release
28. Inhibition of myosin light chain phosphorylation in cultured muscle cells by HA1077, a new type of vasodilator
29. Disorganization by calcium antagonists of actin microfilament in aortic smooth muscle cells
30. Fasudil, a protein kinase inhibitor, prevents the development of endothelial injury and neutrophil infiltration in a two-haemorrhage canine subrarchnoid model
31. Diphosphorylation of myosin light chain and spastic contraction of smooth muscle
32. Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle
33. Intimal hyperplasia enhances myosin light chain phosphorylation in rabbit carotid artery
34. Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077
35. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage
36. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: The role of platelet-derived growth factor
37. Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase
38. The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs
39. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
40. Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder